GlassScriptPhysician profile
Edward J Lee
NPI 1043285190
$5,412.94
in general payments reported to CMS, 2019-2025
46 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $147 · 2021: $165 · 2022: $472 · 2023: $616 · 2024: $1,622 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906 · Long Term Medical Supply Or Device Loan: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.34 |
| Long Term Medical Supply Or Device Loan | $997.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,367.46 | 2019-2025 | |
| Pfizer INC. | $629.85 | 2019-2025 | |
| Janssen Biotech, INC. | $281.32 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $276.51 | 2019-2025 | Eliquis, Camzyos |
| Seagen INC. | $228.28 | 2019-2023 | Adcetris |
| Incyte Corporation | $221.95 | 2019-2025 | Jakafi, Niktimvo |
| Pharmaessentia USA Corporation | $185.87 | 2023-2025 | Besremi |
| Daiichi Sankyo INC. | $166.43 | 2022-2025 | Enhertu, Injectafer |
| Abbvie INC. | $149.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.20 | 2022-2025 | Calquence |
| Glaxosmithkline, LLC. | $129.22 | 2023-2025 | Zejula, Jemperli |
| Amgen INC. | $125.90 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Janssen Pharmaceuticals, INC | $108.66 | 2021-2023 | Xarelto |
| Genentech USA, INC. | $103.78 | 2019-2025 | Itovebi, Venclexta, Phesgo |
| Astellas Pharma US INC | $94.29 | 2019-2025 | Padcev, Xtandi, Vyloy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.